TMEM126B

Across TCGA pan-cancer cohorts, TMEM126B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM126B data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TMEM126B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM126B expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, LSCC, and HNSC are the cancer types where TMEM126B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.893	0.598	.007	11	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.828	.023	7	view →
HNSC	DFS	Quartile	All	0.941	0.632	.010	2	view →
LUAD	OS	Median	II,III,IV	0.893	0.440	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM126B–GBM (DFS)

Open the GBM breakdown →